SANDOZ-DICLOFENAC SUPPOSITORY

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

DICLOFENAC SODIUM

Beschikbaar vanaf:

SANDOZ CANADA INCORPORATED

ATC-code:

M01AB05

INN (Algemene Internationale Benaming):

DICLOFENAC

Dosering:

100MG

farmaceutische vorm:

SUPPOSITORY

Samenstelling:

DICLOFENAC SODIUM 100MG

Toedieningsweg:

RECTAL

Eenheden in pakket:

30

Prescription-type:

Prescription

Therapeutisch gebied:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Product samenvatting:

Active ingredient group (AIG) number: 0114417001; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2021-01-25

Productkenmerken

_Sandoz-Diclofenac and Sandoz-Diclofenac SR _
_ _
_Page 1 of 40 _
PRODUCT MONOGRAPH
PR
SANDOZ-DICLOFENAC
PR
SANDOZ-DICLOFENAC SR
(diclofenac sodium)
50 mg Enteric-Coated Tablets
75 and 100 mg Slow-Release Tablets
50 and 100 mg Suppositories
Acetic Acid Derivatives and Related Substances
Sandoz Canada Inc.
Date of revision:
110 Rue de Lauzon,
January 6, 2020
Boucherville, Quebec
J4B 1E6
Control no. 233855
_Sandoz-Diclofenac and Sandoz-Diclofenac SR _
_ _
_Page 2 of 40 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
15
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
21
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
27
PHARMACEUTICAL INFORMATION
.................